Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02082353Unknown

Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995

Role: collaborator

NCT01346150Unknown

Patients Treated for SCID (1968-Present)

Role: collaborator

NCT01186913Enrolling By Invitation

Natural History Study of SCID Disorders

Role: collaborator

NCT02064933Completed

Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990

Role: collaborator

All 4 trials loaded